You are here

Share:

Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics

Primary tabs

Summary
The promise of RNA interference based therapeutics is made evident by the recent surge of biotechnological drug companies that pursue such therapies and their progression into human clinical trials. The present technology discloses novel RNA  and RNA/DNA nanoparticles including multiple siRNAs, RNA aptamers, fluorescent dyes, and proteins. The National Cancer Institute sees parties interested licensing this technology  or in collaborative research to co-develop RNAi-based nanoparticle therapeutics for cancer and HIV.
NIH Reference Number
E-765-2013
Product Type
Keywords
  • RNAi
  • nanotechnology
  • siRNA
  • nanoparticle, breast cancer
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

The promise of RNA interference based therapeutics is made evident by the recent surge of biotechnological drug companies that pursue such therapies and their progression into human clinical trials. The present invention discloses novel RNA  and RNA/DNA nanoparticles including  multiple siRNAs, RNA aptamers, fluorescent dyes, and proteins. These RNA nanoparticles are useful for various nanotechnological applications. This technology has a higher detection sensitivity and higher silencing efficiencies of targeted genes than conventional siRNAs.  This technology has significant therapeutic potential against multiple disease types, including, cancer and viral infections.  Xxenograft mouse models indicated uptake of the nanoparticles, and six different HIV targets were validated with cell cultures.

Potential Commercial Applications
  • Treatment for cancer and HIV
Competitive Advantages
  • Potential for higher sensitivity, higher efficiency, low cytotoxicity, multiple functionality, multiple targets, and controlled activation
Inventor(s)

Bruce A. Shapiro (NCI), Kirill A. Afonin, Angelica N. Martins, Mathias D. Viard

Development Stage
Publications

Kirill A. Afonin, et al. "Triggering of RNA Interference with RNA-RNA, RNA-DNA, and DNA- RNA Nanoparticles"  [PMID: 25521794]

Patent Status
  • U.S. Patent Filed: U.S. Patent Application Number 15/022,530, Filed 16 Mar 2016
  • Foreign Filed: - Patent Application
Therapeutic Area
Updated
Monday, June 18, 2018